(February 12, 2024, 3:04 PM EST) -- NEW YORK — A federal judge in New York granted a biotechnology company’s motion to dismiss a putative class complaint brought against it by an investor who accused it of misleading investors by failing to disclose that a competitor was working on a cancer treatment similar to its own, finding that the investor did not show how the omission made the company’s statements about its own cancer treatment misleading....